
Alterity Therapeutics Limited ATHE
$ 3.32
-3.52%
Annual report 2022
added 08-31-2022
Alterity Therapeutics Limited Gross Profit 2011-2026 | ATHE
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Alterity Therapeutics Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 177 K | 8.21 M | 4.49 M | 2.53 M | 163 K |
All numbers in AUD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.21 M | 163 K | 3.11 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
1.27 M | - | 2.71 % | $ 14 M | ||
|
Agenus
AGEN
|
-18.3 M | $ 3.27 | -1.8 % | $ 1.17 M | ||
|
Agios Pharmaceuticals
AGIO
|
117 M | $ 29.33 | -2.98 % | $ 1.7 B | ||
|
Akebia Therapeutics
AKBA
|
190 M | $ 1.26 | -3.44 % | $ 324 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | ||
|
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | ||
|
Aligos Therapeutics
ALGS
|
-10.5 M | $ 7.02 | -0.21 % | $ 451 M | ||
|
Alkermes plc
ALKS
|
991 M | $ 29.32 | -2.61 % | $ 4.83 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
195 M | $ 330.95 | -0.59 % | $ 43.4 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M | ||
|
Altimmune
ALT
|
8.18 K | $ 4.2 | -2.55 % | $ 298 M | ||
|
ALX Oncology Holdings
ALXO
|
436 K | $ 2.11 | 0.09 % | $ 110 M | ||
|
Amgen
AMGN
|
19 B | $ 387.85 | 0.03 % | $ 209 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
356 M | $ 20.22 | -0.05 % | $ 945 M | ||
|
Amarin Corporation plc
AMRN
|
166 M | $ 13.62 | -1.3 % | $ 5.55 B | ||
|
AIM ImmunoTech
AIM
|
-643 K | $ 0.92 | 5.25 % | $ 44.2 M | ||
|
Anika Therapeutics
ANIK
|
103 M | $ 14.44 | 0.53 % | $ 212 M | ||
|
ANI Pharmaceuticals
ANIP
|
143 M | $ 75.31 | 1.91 % | $ 1.45 B | ||
|
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-32.3 K | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
2.32 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - | ||
|
Aptorum Group Limited
APM
|
-104 K | $ 0.78 | -0.67 % | $ 4.25 M | ||
|
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | ||
|
Aptevo Therapeutics
APVO
|
4.31 M | $ 7.28 | -0.55 % | $ 2.01 M | ||
|
Albireo Pharma
ALBO
|
39.2 M | - | -0.23 % | $ 916 M | ||
|
Aquestive Therapeutics
AQST
|
32.9 M | $ 3.99 | -0.15 % | $ 346 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
9.54 M | $ 8.11 | -1.44 % | $ 219 M | ||
|
Ardelyx
ARDX
|
4.68 M | $ 6.32 | -3.54 % | $ 1.52 B | ||
|
argenx SE
ARGX
|
2.68 M | $ 762.51 | -0.58 % | $ 25 B |